Thoughts and considerations on Elderly onset Rheumatoid Arthritis: A case-control study of a North African population.

##plugins.themes.academic_pro.article.sidebar##

Published Jun 1, 2025
https://doi.org/10.62438/tunismed.v103i6.5741
Download
pdf
Vol. 103 No. 6 (2025): Tunis Med June 2025

##plugins.themes.academic_pro.article.main##

Kaouther Maatallah
Department of Rheumatology , Kassab orthopedics institute, Ksar Saïd. Faculty of medicine of Tunis, University of Tunis el Manar, Tunisia
Ines Cherif
Department of Rheumatology , Kassab orthopedics institute, Ksar Saïd. Faculty of medicine of Tunis, University of Tunis el Manar, Tunisia
Hanene Ferjani
Department of Rheumatology , Kassab orthopedics institute, Ksar Saïd. Faculty of medicine of Tunis, University of Tunis el Manar, Tunisia
Wafa Triki
Department of Rheumatology , Kassab orthopedics institute, Ksar Saïd. Faculty of medicine of Tunis, University of Tunis el Manar, Tunisia
Dorra Ben Nessib
Department of Rheumatology , Kassab orthopedics institute, Ksar Saïd. Faculty of medicine of Tunis, University of Tunis el Manar, Tunisia
Dhia Kaffel
Department of Rheumatology , Kassab orthopedics institute, Ksar Saïd. Faculty of medicine of Tunis, University of Tunis el Manar, Tunisia
Wafa Hamdi
Department of Rheumatology , Kassab orthopedics institute, Ksar Saïd. Faculty of medicine of Tunis, University of Tunis el Manar, Tunisia

Abstract

Introduction: Rheumatoid arthritis (RA) is the most common chronic inflammatory joint disease, and elderly onset RA starting after age 65 (EORA) is on the rise constituting approximately one-third of RA cases.


Aim: To identify the clinical and therapeutic specificities of EORA.


Methods: This was a cross-sectional case-control study of 224 RA patients (recruitment was done over a 30-month period between 2018 and 2021). Two groups were evaluated:


Elderly onset rheumatoid arthritis (EORA): patients in whom the disease started after the age of 65 and the young-onset rheumatoid arthritis (YORA) control group: patients with disease onset before the age of 65. We collected the clinical characteristics and we compared the therapeutic modalities between both groups:


Results: Our study included 59 patients in the EORA group and 165 patients in the YORA group. The onset of RA in both groups was predominantly progressive and polyarticular. However, in the EORA group, rhizomelic involvement and abrupt onset were significantly more frequent than in the YORA group, with respectively (ORa=4.8 CI=1.5-15.6; p<0.01) and (ORa=5.1 CI=1.8-14; p<0.01). Methotrexate (MTX) was the most frequently used background treatment in both groups. There was no significant difference between the two groups in the prescription of the other conventional DMARDs.


Adverse events were more frequently found in the EORA group (ORa=4.7 CI=1.3-16.4, p<0.05) and consisted mainly of gastrointestinal intolerance.


Rehabilitation was advocated in 6.7% of the EORA group versus 16.9% of the YORA group, with a significant difference (ORa=4.73 [1.36-16.47), p=0.02)...( abstract truncated at 250 words)

Keywords:

Rheumatoid arthritis, Elderly RA, Late-onset RA, EORA, LORA, YORA

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

References

  1. Acuña-Rocha VD, Regalado-Ceballos D, Salcedo-Soto DA, Ramos-Delgado CA, Esquivel-Valerio JA, Hernandez Galarza IJ, et al. Clinical Characteristics of Young-Onset Versus Elderly-Onset Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Cureus. 2024 Nov;16(11):e74148.
  2. Serhal L, Lwin MN, Holroyd C, Edwards CJ. Rheumatoid arthritis in the elderly: Characteristics and treatment considerations. Autoimmun Rev. 2020 Jun;19(6):102528.
  3. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar;31(3):315–24.
  4. Kim HO, Yoon HS, Kwok SK, Ju JH, Park KS, Park SH, et al. Clinical Characteristics of Elderly Onset Rheumatoid Arthritis. J Korean Geriatr Soc. 2010 Dec 1;14(4):227–33.
  5. Pérez N, Gargiulo M de LÁ, Khoury M, Suárez L, Correa M de LÁ, Pera M, et al. Elderly-onset rheumatoid arthritis receives less aggressive therapies than young-onset rheumatoid arthritis in an Argentinian cohort. Reumatol Clin. 2024 Mar;20(3):136–41.
  6. Sugihara T, Ishizaki T, Onoguchi W, Baba H, Matsumoto T, Iga S, et al. Effectiveness and safety of treat-to-target strategy in elderly-onset rheumatoid arthritis: a 3-year prospective observational study. Rheumatol Oxf Engl. 2021 Sep 1;60(9):4252–61.
  7. Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, et al. Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis. 2015 Feb 1;74(2):415–21.
  8. Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatol Oxf Engl. 2012 Dec;51 Suppl 6:vi5-9.
  9. Wilkieson CA, Madhok R, Hunter JA, Capell HA. Toleration, side-effects and efficacy of sulphasalazine in rheumatoid arthritis patients of different ages. Q J Med. 1993 Aug;86(8):501–5.
  10. Kermani TA, Warrington KJ. Polymyalgia rheumatica. Lancet Lond Engl. 2013 Jan 5;381(9860):63–72.
  11. Chiu YM, Lai MS, Lin HY, Lang HC, Lee LJH, Wang JD. Disease activity affects all domains of quality of life in patients with rheumatoid arthritis and is modified by disease duration. Clin Exp Rheumatol. 2014 Dec;32(6):898–903.
  12. Aletaha D. Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials. Ann Rheum Dis. 2006 Feb;65(2):227–33.
  13. Treharne GJ, Douglas KMJ, Iwaszko J, Panoulas VF, Hale ED, Mitton DL, et al. Polypharmacy among people with rheumatoid arthritis: the role of age, disease duration and comorbidity. Musculoskeletal Care. 2007 Dec;5(4):175–90.
  14. Cho SK, Sung YK, Choi CB, Cha HS, Choe JY, Chung WT, et al. Do patients with elderly-onset rheumatoid arthritis have severe functional disability? Semin Arthritis Rheum. 2012 Aug;42(1):23–31.
  15. Pease CT, Bhakta BB, Devlin J, Emery P. Does the age of onset of rheumatoid arthritis influence phenotype?: a prospective study of outcome and prognostic factors. Rheumatol Oxf Engl. 1999 Mar;38(3):228–34.
  16. Roux C. Osteoporosis in inflammatory joint diseases. Osteoporos Int J Establ Result Coop Eur Found Osteoporos Natl Osteoporos Found USA. 2011 Feb;22(2):421–33.
  17. Figus FA, Piga M, Azzolin I, McConnell R, Iagnocco A. Rheumatoid arthritis: Extra-articular manifestations and comorbidities. Autoimmun Rev. 2021 Apr;20(4):102776.
  18. Curi YS, Lucero LG, Hüttmann FJ, Leguizamón ML, Mazza SM, Espasa GV, et al. Fri0603-Hpr Comorbidities in Rheumatoid Arthritis: Utility of Raci Score (rheumatoid Arthritis Comorbidity Index). Ann Rheum Dis. 2020 Jun 1;79(Suppl 1):907–8.
  19. Kłodziński Ł, Wisłowska M. Comorbidities in rheumatic arthritis. Reumatologia. 2018;56(4):228–33.
  20. Salomon-Escoto K, Kay J. The “Treat to Target” Approach to Rheumatoid Arthritis. Rheum Dis Clin North Am. 2019 Nov;45(4):487–504.
  21. Lee JL, Sinnathurai P, Buchbinder R, Hill C, Lassere M, March L. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study. Arthritis Res Ther. 2018;20:171.
  22. Schjerning AM, McGettigan P, Gislason G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020 Sep;17(9):574–84.
  23. Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis. 2012 Jul;71(7):1128–33.
  24. Kumagai K, Okumura N, Amano Y, Yayama T, Mimura T, Maeda T, et al. Consideration of differences in drug usage between young-onset and elderly-onset rheumatoid arthritis with target of low disease activity. Mod Rheumatol. 2021 Nov;31(6):1094–9.
  25. Takanashi S, Kaneko Y. Unmet Needs and Current Challenges of Rheumatoid Arthritis: Difficult-to-Treat Rheumatoid Arthritis and Late-Onset Rheumatoid Arthritis. J Clin Med. 2024 Dec 13;13(24):7594.
  26. Baimukhamedov Ch. Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist. Rheumatol Sci Pract. 2020 Sep 4;58(4):447–50.
  27. Boots AMH, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013 Oct;9(10):604–13.
  28. Kearsley-Fleet L, Zavada J, Hetland ML, Nordstrom DC, Aaltonen KJ, Listing J, et al. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology. 2015 Jun 1;54(6):1074–9.
  29. Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J Rheumatol. 2006 Feb;33(2):234–43.
  30. Payet S, Soubrier M, Perrodeau E, Bardin T, Cantagrel A, Combe B, et al. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry. Arthritis Care Res. 2014 Sep;66(9):1289–95.
  31. Metsios GS, Kitas GD. Physical activity, exercise and rheumatoid arthritis: Effectiveness, mechanisms and implementation. Best Pract Res Clin Rheumatol. 2018 Oct;32(5):669–82.
  32. Roodenrijs NMT, Hamar A, Kedves M, Nagy G, van Laar JM, van der Heijde D, et al. Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis. RMD Open. 2021 Jan;7(1):e001512.
  33. Küçükdeveci AA. Nonpharmacological treatment in established rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2019 Oct;33(5):101482.
  34. Ben Tekaya A, Rouached L, Ben Dhia S, Bouden S, Tekaya R, Mahmoud I, et al. Physical activity assessment in rheumatoid arthritis: a 120-patient cross-sectional study. Tunis Med. 2024 Jun 5;102(6):348–53.
  35. Nikiphorou E, Konan S, MacGregor AJ, Haddad FS, Young A. The surgical treatment of rheumatoid arthritis: a new era? Bone Jt J. 2014 Oct;96-B(10):1287–9.
  36. Zhou VY, Lacaille D, Lu N, Kopec JA, Garbuz DS, Qian Y, et al. Has the incidence of total joint arthroplasty in rheumatoid arthritis decreased in the era of biologics use? A population-based cohort study. Rheumatol Oxf Engl. 2022 May 5;61(5):1819–30.